Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | An update on CARTITUDE-2: cilta-cel in patients with multiple myeloma in second line

Hermann Einsele • 11 Jun 2022
EHA 2022
Multiple Myeloma CAR-T Ciltacabtagene autoleucel
CARTITUDE-1 CARTITUDE-2

Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, gives an update on the CARTITUDE-2 study (NCT04133636) evaluating the safety and efficacy of ciltacabtagene autoleucel (cilta-cel) in patients with multiple myeloma in the second-line setting. The study did not report increased rates of toxicity when compared to CARTITUDE-1 (NCT03548207). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Hermann Einsele

2:44
Moving CAR-T into earlier lines of therapy in multiple myeloma
Hermann Einsele • 17 Feb 2024
0:45
CAR T-cell therapy in lenalidomide-refractory multiple myeloma
Hermann Einsele • 17 Feb 2024
1:19
Sequencing bispecific antibodies and CAR-T therapy & the evolving role of bispecifics in myeloma
Hermann Einsele • 26 Jun 2023
8:16
Results from CARTITUDE-4: cilta-cel for lenalidomide-refractory multiple myeloma
Hermann Einsele • 26 Jun 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals